Verve Therapeutics, Inc. ( (VERV) ) has released its Q4 earnings. Here is a breakdown of the information Verve Therapeutics, Inc. presented to its investors.
Verve Therapeutics, Inc. is a clinical-stage company focused on developing genetic medicines for cardiovascular disease, aiming to transform treatment from chronic therapies to single-course gene editing solutions. The company recently reported its financial results for the fourth quarter and full year 2024, highlighting significant progress in its clinical pipeline and financial performance. Key developments include the ongoing enrollment in the Heart-2 Phase 1b clinical trial for VERVE-102, targeting PCSK9, and the Pulse-1 Phase 1b clinical trial for VERVE-201, targeting ANGPTL3. The company also announced a cash position of $524.3 million, expected to fund operations into mid-2027, and a notable increase in collaboration revenue compared to the previous year. Looking ahead, Verve anticipates several milestones in 2025, including initial data from the Heart-2 trial and a decision from Eli Lilly on the PCSK9 program, positioning the company for continued advancement in its mission to address cardiovascular disease.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com